Clinical Trials Arena January 21, 2025
Whilst vaccines exist for animals, none are commercially available for human use for the mosquito-borne virus.
South African biotech Afrigen Biologics has secured a $6.2m grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop the first mRNA-based vaccine against Rift Valley fever.
The funding will see Afrigen’s researchers work with the International Vaccine Institute (IVI) to advance the mRNA candidate through preclinical testing and into a Phase I clinical trial in humans. The trial will either be conducted in South Africa or another country affected by an outbreak of the mosquito-borne disease.
Rift Valley fever was first identified more than 90 years ago in Kenya. The disease occurs in humans after contact with infected animals, meaning pastoral farmers...
Today's Sponsors
Today's Sponsor